<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (t-MDSs) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) have a poor prognosis with conventional therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Encouraging results are reported after allogeneic transplantation </plain></SENT>
<SENT sid="2" pm="."><plain>We analyzed outcomes in 868 persons with t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (n = 545) or t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (n = 323) receiving allogeneic transplants from 1990 to 2004 </plain></SENT>
<SENT sid="3" pm="."><plain>A myeloablative regimen was used for conditioning in 77% </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment-related mortality (TRM) and relapse were 41% (95% confidence interval [CI], 38-44) and 27% (24-30) at 1 year and 48% (44-51) and 31% (28-34) at 5 years, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Disease-free (DFS) and overall survival (OS) were 32% (95% CI, 29-36) and 37% (34-41) at 1 year and 21% (18-24) and 22% (19-26) at 5 years, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>In multivariate analysis, 4 risk factors had adverse impacts on DFS and OS: (1) age older than 35 years; (2) poor-risk cytogenetics; (3) t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> not in remission or advanced t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; and (4) donor other than an HLA-identical sibling or a partially or well-matched unrelated donor </plain></SENT>
<SENT sid="7" pm="."><plain>Five-year survival for subjects with none, 1, 2, 3, or 4 of these risk factors was 50% (95% CI, 38-61), 26% (20-31), 21% (16-26), 10% (5-15), and 4% (0-16), respectively (P &lt; .001) </plain></SENT>
<SENT sid="8" pm="."><plain>These data permit a more precise prediction of outcome and identify subjects most likely to benefit from allogeneic transplantation </plain></SENT>
</text></document>